Syntopia provides a pump‑free microfluidic platform that creates uniform, scalable 3D cell cultures and organoids compatible with standard robotic liquid‑handling systems for high‑throughput experiments. The open‑format chips support multi‑modal readouts—including immunofluorescence imaging, secretome profiling, and RNA sequencing—delivering comprehensive data sets optimized for AI‑driven drug discovery and predictive toxicity modeling.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech and pharmaceutical researchers often rely on 2D cell cultures or low-throughput 3D models that fail to capture complex tissue physiology, leading to poor predictive power and high clinical failure rates. Generating large, high‑quality datasets from 3D cultures typically requires specialized equipment, manual handling, and limited assay readouts.
Solution
Syntopia offers a microfluidic platform that creates scalable 3D cell cultures and organoids without the need for pumps or dedicated instrumentation. The open‑format system integrates with standard laboratory robotics, enabling high‑throughput experiments and automated handling. After treatment, the platform supports multi‑modal readouts—including immunofluorescence imaging, secretome chemical analysis, and RNA sequencing—to provide comprehensive cellular response data. Its modular design allows customization for specific applications such as oncology, immuno‑oncology, and hepatotoxicity studies, delivering datasets suitable for AI‑driven drug discovery and predictive modeling.
Target Audience
Primary customers are biotech companies and pharmaceutical research teams that require high‑throughput, physiologically relevant 3D models for target validation, efficacy screening, and toxicity assessment.
Features
- Pump‑free microfluidic chips that generate uniform 3D cultures and organoids at scale
- Compatibility with existing robotic liquid‑handling systems for fully automated high‑throughput workflows
- Open‑format design permitting easy integration of diverse assay configurations and custom device geometries
- Multi‑modal readout capability: immunofluorescence imaging, secretome chemical profiling, and post‑treatment RNA sequencing
- Modular application templates for 3D oncology/immuno‑oncology functional assays (e.g., migration, cytotoxicity, CAR‑T/NK screening) and long‑term hepatocyte toxicity models (>21 days)
- Data output optimized for AI and in silico modeling to improve predictivity in drug discovery pipelines